Business / Finance

RSS

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

Almac Discovery today announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd for clinical development and marketing in South Korea.

29 Apr 2013

Simulations Plus to distribute quarterly cash dividend in May 2013

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a cash dividend in May.

26 Apr 2013

HMS Holdings revenue increases 8.7% to $116.6M in first quarter 2013

HMS Holdings Corp. today announced financial results for its first quarter ended March 31, 2013 and provided revised 2013 guidance.

26 Apr 2013

Sectra signs agreement to distribute healthcare IT suite in Puerto Rico

International medical imaging IT company, Sectra announces an exclusive agreement with Answer Medical Solutions to distribute its healthcare IT suite throughout Puerto Rico.

26 Apr 2013

DJO Global reports first quarter results for 2013

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC ("DJOFL"), for the first quarter ended March 30, 2013.

26 Apr 2013

Scioderm completes Series A financing commitment totaling $16 million

Scioderm, a company developing novel dermatology therapeutics, today announced the completion of a Series A financing commitment totaling $16 million. Morgenthaler Ventures led the Series A financing, with Technology Partners as the second investor participating in the round.

26 Apr 2013

Lifepoint Hospitals’ revenues increase 9.4% to $931.1 million in first quarter 2013

LifePoint Hospitals, Inc. today announced results for the first quarter ended March 31, 2013. For the first quarter ended March 31, 2013, revenues from continuing operations were $931.1 million, up 9.4% from $851.0 million for the same period a year ago.

26 Apr 2013

Covidien net sales increase 5% to $3.10 billion in second quarter 2013

Covidien plc today reported results for the second quarter of fiscal 2013 (January - March 2013). Second-quarter net sales of $3.10 billion increased 5% from the $2.95 billion reported in the second quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by two percentage points.

26 Apr 2013

New Haven Pharmaceuticals gets venture loan facility from Horizon Technology Finance

Horizon Technology Finance Corporation ("Horizon"), a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and clean-tech industries, today announced it has closed a $2 million venture loan facility with New Haven Pharmaceuticals, Inc. ("NHP"), a developer of prescription pharmaceuticals that utilize currently marketed drugs or active pharmaceutical ingredients generally recognized as safe for use in therapeutic applications.

26 Apr 2013

Immudex signs agreement to provide MHC-peptide multimer and Elispot proficiency panel services

Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.

26 Apr 2013

Universal Health Services net revenues increase 2% to $1.83 billion in first quarter 2013

Universal Health Services, Inc. announced today that its reported net income attributable to UHS was $119.8 million, or $1.21 per diluted share, during the first quarter of 2013 as compared to $128.6 million, or $1.31 per diluted share, during the comparable quarter of 2012.

26 Apr 2013

Molina Healthcare reports strong quarterly results for 2013

Molina Healthcare, Inc. today reported its financial results for the quarter ended March 31, 2013.

26 Apr 2013

Dyax reports Q1 2013 financial results; LFRP portfolio continues to be a growth driver

Dyax Corp. today announced financial results for the first quarter ended March 31, 2013. The Company will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and updates regarding its key value drivers - the KALBITOR® (ecallantide) business, the broader angioedema portfolio and the Licensing and Funded Research Program (LFRP).

26 Apr 2013

Rochester Medical's net sales increase 8% to $16,635,000 in second quarter 2013

Rochester Medical Corporation today announced operating results for its second quarter ended March 31, 2013. The Company reported sales of $16,635,000 for the current quarter compared to $15,427,000 for the second quarter of last year. The Company also reported net income of $1,199,000 or $0.10 per diluted share compared to $603,000 or $0.05 per diluted share for the same period last year.

26 Apr 2013

Cempra reports net loss of $10.3 million in first quarter 2013

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013.

26 Apr 2013

Greatbatch reports 19% increase in adjusted diluted EPS targets for first quarter 2013

Greatbatch, Inc., today announced results for its first quarter ended March 29, 2013 highlighted by a 19% increase in adjusted diluted EPS despite negative 4% constant currency organic revenue growth.

26 Apr 2013

IGI Laboratories net revenues increase 101% to $3.7M in first quarter 2013

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the first quarter ended March 31, 2013.

26 Apr 2013

Comparison of processability of medical resins reveals effect of physical properties on moldability

Both physical properties and processability play key roles when injection-molded parts are mass produced. When producing medical parts, a consistent, high degree of accuracy is also vital. It is relatively simple to adjust a process to account for differences in molecular weight once that process is optimized for a specific polymer. It is much more complex to adjust the process for changes in polymers.

25 Apr 2013

Rheumatoid arthritis diagnosis: an interview with Dr. Stan Naides, Medical Director, Quest Diagnostics

Rheumatoid arthritis (RA) is an autoimmune disorder that can cause debilitating joint damage. In cases of RA, the immune system attacks the body’s own tissues, especially the membranes that line the joints. As a result, fluid builds up in the joints, causing pain and systemic inflammation, leading to joint destruction if untreated.

From Quest Diagnostics 23 Apr 2013

Drug delivery system discussions between mPhase Technologies, Inc. and major European Drug Company

mPhase Technologies, Inc. (OTCBB: XDSL) reported today that it has commenced the discussion of its drug delivery system with a major European Drug Company. The discussions were arranged through mPhase's continuing relationship with Invest In France, an agency of the French government.

23 Apr 2013

Business / Finance

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

Simulations Plus to distribute quarterly cash dividend in May 2013

HMS Holdings revenue increases 8.7% to $116.6M in first quarter 2013

Sectra signs agreement to distribute healthcare IT suite in Puerto Rico

DJO Global reports first quarter results for 2013

Scioderm completes Series A financing commitment totaling $16 million

Lifepoint Hospitals’ revenues increase 9.4% to $931.1 million in first quarter 2013

Covidien net sales increase 5% to $3.10 billion in second quarter 2013

New Haven Pharmaceuticals gets venture loan facility from Horizon Technology Finance

Immudex signs agreement to provide MHC-peptide multimer and Elispot proficiency panel services

Universal Health Services net revenues increase 2% to $1.83 billion in first quarter 2013

Molina Healthcare reports strong quarterly results for 2013

Dyax reports Q1 2013 financial results; LFRP portfolio continues to be a growth driver

Rochester Medical's net sales increase 8% to $16,635,000 in second quarter 2013

Cempra reports net loss of $10.3 million in first quarter 2013

Greatbatch reports 19% increase in adjusted diluted EPS targets for first quarter 2013

IGI Laboratories net revenues increase 101% to $3.7M in first quarter 2013

Comparison of processability of medical resins reveals effect of physical properties on moldability

Rheumatoid arthritis diagnosis: an interview with Dr. Stan Naides, Medical Director, Quest Diagnostics

Drug delivery system discussions between mPhase Technologies, Inc. and major European Drug Company

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News